Kellogg settles with FTC
This article was originally published in The Tan Sheet
Executive Summary
Kellogg Co. settles Federal Trade Commission allegations that it falsely advertised Frosted Mini-Wheats as "clinically shown to improve kids' attentiveness by nearly 20 percent." The commission alleged that the study Kellogg relied on for the claim shows only one in nine children's attentiveness improved by 20 percent or more, according to an April 20 FTC release. The commission also alleged that the study shows children who ate the cereal for breakfast were on average 11 percent more attentive than those who skipped breakfast. This contradicts the company's claim that attentiveness improved 20 percent, the commission says. The settlement prohibits Kellogg from making unsubstantiated claims and misrepresenting study results, but does not impose a fine or consumer redress
You may also be interested in...
FTC finalizes Kellogg consent order
The Federal Trade Commission approves a final consent order to resolve allegations Kellogg Company falsely advertised Frosted Mini-Wheats as "clinically shown to improve kids' attentiveness nearly 20 percent." The Commission said data Kellogg relied on to make the claim was self-contradictory and did not support the statement (1"The Tan Sheet" April 27, 2009)
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.